bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026

bioAffinity Technologies said sales of its CyPath Lung test increased more than 100% through the third quarter of 2026 compared with the same period in 2025. The company attributed the growth to continued clinical adoption of the noninvasive test for assessing lung cancer likelihood in high-risk individuals.

Analysis

The sales-growth figure is an adoption signal, not yet evidence of material earnings leverage: without absolute test volume, realized price, reimbursement mix, and contribution margin, growth may be coming off a small base and may not translate into cash generation. Because this is a company-reported update, verify it against quarterly revenue, test counts, and cash-flow disclosures before underwriting a durable commercial inflection.

Over the next 1–3 months, the key catalysts are reported revenue conversion, evidence of repeat ordering across clinical sites, and clarity on payer coverage and the test’s place alongside established lung-screening pathways. Over 6–18 months, broader adoption could improve operating leverage for BIAF; conversely, weak reimbursement, limited physician uptake, or a need for continued financing would dilute the value of volume growth. Established screening and diagnostic pathways are the competitive constraint; this update alone does not establish displacement or a change in standard of care.

Contrarian read: the growth rate may attract momentum buyers, while the market may be underweight the distinction between percentage growth and commercially meaningful scale. Equally, if absolute volumes and economics are already improving, treating the update as merely promotional could miss an early inflection. No trade is warranted from this release alone; favor confirmation over chasing the headline.

Key Decisions for Investors

• Keep BIAF on a catalyst watchlist rather than initiating a directional position on the percentage-growth claim alone.
• On the next results, verify absolute tests performed, recognized revenue, realized price or reimbursement, gross-profit contribution, clinical-site expansion, and cash runway; upgrade the thesis only if volume growth converts into improving unit economics without disproportionate cash burn.
• For an existing BIAF position, treat any sharp post-release rally without corroborating operating metrics as vulnerable to reversal; reassess if subsequent disclosures show slowing test volumes, weak revenue conversion, or worsening liquidity.
• Falsification of the bullish adoption thesis: the next reported period fails to show continued test-volume growth or meaningful revenue conversion, or management identifies reimbursement, workflow, or financing constraints that impede commercialization.